Bullish & Foolish
--
--

Is SS Innovations International going out of business?

Loading the full analysis
Reading the filings

SS INNOVATIONS INTERNATIONAL, INC. (SSII) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

SS INNOVATIONS INTERNATIONAL, INC. (SSII) scores 27 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Quality score 27/100
Rating Distressed / Caution
Sector Biotech/Pharma
Market cap $683.3M
Last close $3.41
Revenue growth (YoY) 89.7%
FCF margin (TTM) -59.4%
Dividend yield 0.0%

Leading signal: ROIC: -19.67%

Five questions, kept separate

Survival - Critical
4-7 mo of estimated runway from 2026-06-30, based on $13.6M of cash and short-term investments against $31.1M of annual burn.
Business quality - Poor
-15.8% operating margin and -59.4% FCF margin produce a poor Business Quality assessment.
Trajectory - Clinical progress unavailable
Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.
Valuation - Extreme expectations
-4.8% FCF yield supports an extreme expectations Valuation assessment on the ttm basis.
Event risk - Evidence unavailable
No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

  • Debt / Equity: -0.19x (Net Cash)
  • ROIC: -19.67%
  • Interest coverage: -20.4x
  • Cash Runway (years): 0.44y
  • Revenue CAGR (3Y): 209.27%
  • Return on Assets: -12.82%
  • Revenue per Asset Efficiency: 17.24% QoQ (Strong monetization)
  • Revenue growth YoY: 39.39% (YoY) - Growth from a low base; sustainability uncertain.
  • FCF margin: -59.37% (Inv. Mode)
  • Asset Growth Velocity: 38.59% YoY (Scaling infra)
  • Cash Burn Deceleration: -120.34% QoQ improvement (Worsening)
  • Revenue Quality: Quality concerns (DSO +40d, Rev +39%)

Read from filings through 2026-08-13.

Price as of 2026-09-07.

Headline score detail

Source coverage and limitations
--
Reference Links